TITLE

The Risks and Benefits of HPV Vaccination

AUTHOR(S)
Haug, Charlotte
PUB. DATE
August 2009
SOURCE
JAMA: Journal of the American Medical Association;8/19/2009, Vol. 302 Issue 7, p795
SOURCE TYPE
Academic Journal
DOC. TYPE
Editorial
ABSTRACT
The author comments on the risks and beneficial effects of human papillomavirus (HPV) vaccine. She examines the theory behind the vaccine, and argues on the right vaccine that could prevent HPV infection. She discusses the two papers published which present significant data that may influence decisions about HPV vaccination. She also argues that the net benefit of the vaccine to a woman is still uncertain.
ACCESSION #
43788830

 

Related Articles

  • Choice of cancer vaccine is branded a missed opportunity by charities. Kmietowicz, Zosia // BMJ: British Medical Journal (International Edition);6/28/2008, Vol. 336 Issue 7659, p1456 

    The article discusses how health charities are criticizing the adoption of the drug Cervarix into national immunisation initiatives in Great Britain. Cervarix, developed by the pharmaceutical firm GlaxoSmithKline is designed to vaccinate women against human papillomaviruses, which can cause...

  • Appendix 1: Model protocol for the manufacturing and control of recombinant human papillomavirus virus-like particle vaccines.  // WHO Technical Report Series;2016, Issue 999, p216 

    An appendix is presented of model protocol for manufacturing and control of recombinant human papillomavirus virus-like particle vaccines from the World Health Organization.

  • Appendix 2: Model NRA Lot Release Certificate for recombinant human papillomavirus virus-like particle vaccines.  // WHO Technical Report Series;2016, Issue 999, p232 

    An appendix is presented of model NRA Lot Release Certificate for recombinant human papillomavirus virus-like particle vaccines from the World Health Organization Expert Committee on Biological Standardization.

  • In the mood for wiping out vaccine-preventable diseases. Fleck, Fiona // Bulletin of the World Health Organization;Apr2014, Vol. 92 Issue 4, p236 

    An interview with executive vice president of the Sabin Vaccine Institute, Ciro de Quadros, is presented. He discusses how he became interested in immunization while involved with a smallpox programme in Brazil in 1969, what disease surveillance and containment is and how he helped to develop...

  • Recommended Adult Immunization Schedule -- United States, October 2005--September 2006.  // MMWR: Morbidity & Mortality Weekly Report;10/14/2005, Vol. 54 Issue 40, pQ-1 

    Focuses on the recommended Adult Immunization Schedule in the U.S. for October 2005 to September 2006. Difference of the 2005-2006 schedule from the previous schedule; Recommended dose of tetanus diphtheria vaccine for people aged 50-64 years; Web sites to access for further information on...

  • Do Vaccines Save Lives? Yes They Do! LERNOUT, Tinne; THEETEN, Heidi; LEURIDAN, Elke; VAN DAMME, Pierre // Acta Medica Portuguesa;mar/abr2014, Vol. 27 Issue 2, p160 

    Since their introduction and widespread use, vaccines have been very successful in reducing morbidity and mortality of the diseases they target, at an individual level and through herd immunity. The impact on the mortality has been rapid and easy to measure for some diseases, such as diphtheria,...

  • Vaccine development strategies for improving immunization: the role of modern immunology. Levine, Myron M.; Sztein, Marcelo B. // Nature Immunology;May2004, Vol. 5 Issue 5, p460 

    An ideal vaccine has certain biological and physical characteristics. Technological advances have provided new strategies that may help the design of such a vaccine.

  • A Prospective Study of the Effectiveness of the New Zealand Meningococcal B Vaccine. Colleen Kelly; Richard Arnold; Yvonne Galloway; Jane OHallahan // American Journal of Epidemiology;Oct2007, Vol. 166 Issue 7, p817 

    The effectiveness of a new group B strain-specific meningococcal vaccine referred to as “MeNZB,” developed by Chiron Vaccines (Siena, Italy) in collaboration with the Norwegian Institute of Public Health, was assessed in a prospective observational study following a...

  • Acute viscerotropic disease following vaccination against yellow fever. Hayes, Edward B. // Transactions of the Royal Society of Tropical Medicine & Hygiene;Oct2007, Vol. 101 Issue 10, p967 

    Summary: Acute viscerotropic disease following yellow fever vaccination (YEL-AVD) is a rare but serious complication of vaccination with 17D yellow fever vaccine. This paper reviews the existing literature regarding YEL-AVD and discusses possible etiologic mechanisms. A greater understanding of...

  • Successful Booster Antibody Response up to 54 Months after Single Primary Vaccination with Virosome-Formulated, Aluminum-Free Hepatitis A Vaccine. Beck, Bernhard R.; Hatz, Christoph; Brönnimann, Rainer; Herzog, Christian // Clinical Infectious Diseases;11/1/2003, Vol. 37 Issue 9, p126 

    This study demonstrates that a booster dose of the virosome-formulated, aluminum-free hepatitis A vaccine Epaxal (Berna Biotech) is highly immunogenic in subjects who received a single primary dose of this vaccine 18–54 months earlier. There were no significant differences in geometric...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics